Shots:

• The P-III study involves assessing of SB3 vs Herceptin in 208 Chinese breast cancer patients and plans to evaluate its safety and efficacy
• Samsung plans to conduct the trial in collaboration with AffaMed Therapeutics- a Chinese venture established by C-Bridge Capital
• Ontruzant is a (biosimilar- trastuzumab) and is targeted to treat patients with early breast cancer- metastatic breast cancer- and metastatic gastric cancer and is also approved in the EU. Additionally- Samsung Bioepis has four biosimilars SB3 (Herceptin)- SB11 ( Lucentis)- SB12 ( Soliris)- and SB15 ( Eylea)

Click here to read full press release/ article

 Ref: Samsung Bioepis | Image: Samsung Bioepis